Supplementary Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Jun. 30, 2020

In millions, except per share amounts	Quarters Ended
	Jun 30,			Mar 31,			Dec 31,			Sep 30,
Consolidated Statement of Operations Data:	2019			2019			2018			2018
Molecular diagnostic testing	$	196.9		$	200.5		$	203.0		$	189.0
Pharmaceutical and clinical services		18.5			16.1			13.8			13.3
Total revenue		215.4			216.6			216.8			202.3
Costs and expenses:
Cost of molecular diagnostic testing		41.6			40.3			44.0			42.3
Cost of pharmaceutical and clinical services		9.0			8.3			8.1			7.4
Research and development expense		20.9			21.5			22.4			21.1
Change in contingent consideration		(0.3	)		—			1.0			0.4
Selling, general and administrative expense		149.8			140.6			135.2			129.9
Total costs and expenses		221.0			210.7			210.7			201.1
Operating income (loss)		(5.6	)		5.9			6.1			1.2
Other income (expense):
Interest income		0.9			0.7			0.9			0.7
Interest expense		(3.2	)		(3.2	)		(3.4	)		(2.2	)
Other		0.2			(0.1	)		—			1.1
Total other income (expense)		(2.1	)		(2.6	)		(2.5	)		(0.4	)
Income (loss) before income taxes		(7.7	)		3.3			3.6			0.8
Income tax provision (benefit)		(3.4	)		(3.6	)		1.0			1.6
Net income (loss)		(4.3	)		6.9			2.6			(0.8	)
Net loss attributable to non-controlling interest		(0.1	)		—			—			(0.1	)
Net income (loss) attributable to Myriad Genetics, Inc. stockholders	$	(4.2	)	$	6.9		$	2.6		$	(0.7	)
Earnings (loss) per share:
Basic	$	(0.06	)	$	0.09		$	0.04		$	(0.01	)
Diluted	$	(0.06	)	$	0.09		$	0.03		$	(0.01	)
Weighted average shares outstanding:
Basic		73.4			73.3			74.2			73.0
Diluted		74.8			74.9			76.5			73.0